Pay in 4 interest-free payments of $6.39 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
It can dominate your thoughts, drain your mental energy, and leave you feeling ashamed for wanting food so badly
With the development of the first GIP/GLP-1 co-agonist, tirzepatide, there has been an exponential increase in the effectiveness of incretin-mimetic pharmacological therapy for weight control in obese patients with and without diabetes
Tirzepatide is a prescription medication that activates two receptors involved in appetite regulation and blood sugar control: GIP and GLP-1
The findings are based on analysis of data from 2.4 million participants
While these measures will not have the same magnitude impact as prescription GLP-1 drugs they avoid the high price tag and side effects that can accompany the GLP-1 drugs
US$ 27.79
US$ 26.95
US$ 27.15
